Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**EUK-207** is a synthetic **small molecule** mimetic of superoxide dismutase (SOD) and catalase enzymes, designed to catalyze the dismutation of superoxide radicals to hydrogen peroxide and subsequently decompose hydrogen peroxide to water and oxygen, thereby scavenging reactive oxygen species (ROS). It has demonstrated neuroprotective effects in preclinical models by reducing oxidative stress, lipid peroxidation, and apoptosis in oxygen-glucose deprivation (OGD)-induced hippocampal slice cultures, reversing age-related learning deficits in mice, and mitigating radiation-induced skin dermatitis, cognitive impairment, and lung damage in rats. Additionally, long-term administration suppressed plaque development and endothelial activation in atherosclerosis mouse models. Initially developed by **Tyrian Diagnostics**, its development has been **discontinued**.[1][2][3][4][5][9]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on EUK-207.